Index of reports
> Cases with Headache (2)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Robaxin (Methocarbamol) where reactions include headache. The selected reports were submitted to the FDA during the sample period of about a year.
Possible Robaxin side effects in female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-03-15
Patient: female, weighing 89.4 kg (196.7 pounds)
Reactions: Dysarthria, Polymedication, Mental Status Changes, Headache, Hypertension, Asthenia, Hypokalaemia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Lexapro
Administration route: Oral
Indication: Post-Traumatic Stress Disorder
Ambien
Administration route: Oral
Indication: Insomnia
Lyrica
Administration route: Oral
Indication: Fibromyalgia
Clonazepam
Administration route: Oral
Indication: Bipolar Disorder
Ibuprofen
Administration route: Oral
Indication: Fibromyalgia
Placebo
Administration route: Oral
Start date: 2008-11-29
End date: 2008-12-24
Lexapro
Administration route: Oral
Indication: Bipolar Disorder
Robaxin
Indication: Fibromyalgia
Zestoretic
Dosage: 20/12.5 daily
Administration route: Oral
Indication: Hypertension
Start date: 2008-12-04
Desvenlafaxine Succinate Monohydrate
Administration route: Oral
Indication: Menopausal Symptoms
Start date: 2008-09-09
End date: 2008-11-22
Placebo
Administration route: Oral
Indication: Menopausal Symptoms
Start date: 2008-09-09
End date: 2008-11-22
Loratadine
Administration route: Oral
Indication: Seasonal Allergy
Vicodin
Dosage: 5/500 as needed
Administration route: Oral
Indication: Fibromyalgia
Vivelle
Indication: Hormone Replacement Therapy
Desvenlafaxine Succinate Monohydrate
Administration route: Oral
Start date: 2008-11-29
End date: 2008-12-24
Abilify
Administration route: Oral
Indication: Bipolar I Disorder
Fluticasone
Indication: Seasonal Allergy
Possible Robaxin side effects in female
Reported by a health professional (non-physician/pharmacist) from United States on 2011-12-23
Patient: female, weighing 89.4 kg (196.7 pounds)
Reactions: Dysarthria, Polymedication, Mental Status Changes, Headache, Hypertension, Asthenia, Hypokalaemia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Desvenlafaxine Succinate Monohydrate
Administration route: Oral
Start date: 2008-09-09
End date: 2008-11-22
Lexapro
Indication: Ill-Defined Disorder
Fluticasone Furoate
Indication: Ill-Defined Disorder
Loratadine
Indication: Ill-Defined Disorder
Vicodin
Dosage: 5/500 as needed
Indication: Ill-Defined Disorder
Ambien
Administration route: Oral
Indication: Ill-Defined Disorder
Lyrica
Indication: Ill-Defined Disorder
Placebo
Administration route: Oral
Indication: Menopausal Symptoms
Start date: 2008-09-09
End date: 2008-11-22
Abilify
Indication: Ill-Defined Disorder
Vivelle
Indication: Ill-Defined Disorder
Zestoretic
Dosage: 20/12.5 daily
Indication: Ill-Defined Disorder
Desvenlafaxine Succinate Monohydrate
Administration route: Oral
Indication: Menopausal Symptoms
Start date: 2008-11-29
End date: 2008-12-24
Robaxin
Indication: Ill-Defined Disorder
Ibuprofen
Indication: Ill-Defined Disorder
Placebo
Administration route: Oral
Start date: 2008-11-29
End date: 2008-12-24
Clonazepam
Indication: Ill-Defined Disorder
|